Clarity Pharmaceuticals (Clarity Pharmaceuticals) EV-to-Revenue : (As of May. 24, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Clarity Pharmaceuticals's enterprise value is $830.98 Mil. Clarity Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Clarity Pharmaceuticals's EV-to-Revenue for today is .

The historical rank and industry rank for Clarity Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CLRPF's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.22
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), Clarity Pharmaceuticals's stock price is $2.90. Clarity Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Clarity Pharmaceuticals's PS Ratio for today is .

Clarity Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Clarity Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals EV-to-Revenue Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

EV-to-Revenue

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarity Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Clarity Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's EV-to-Revenue falls into.

Clarity Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Clarity Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	830.982	/	0
	=

Clarity Pharmaceuticals's current Enterprise Value is $830.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clarity Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Clarity Pharmaceuticals (OTCPK:CLRPF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Clarity Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.90	/	0
	=

Clarity Pharmaceuticals's share price for today is $2.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.

Clarity Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.